Author

A. Y. Patel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Drakaki· 2 shared A. Ribas· 2 shared A. T. Hoang· 2 shared H.-C. Chen· 2 shared M. A. Su· 2 shared M. G. Lechner· 2 shared P. Famini· 2 shared T. E. Angell· 2 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Drakaki

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8+ T cells Driven by IL21 Contribute to Checkpoint Inhibitor Thyroiditis

M. G. Lechner, Z. Zhou, A. T. Hoang, N. Huang, J. Ortega, L. N. Scott, H.-C. Chen, A. Y. Patel, R. Y. Tafti, K. Kim, W. Hugo, P. Famini, A. Drakaki, A. Ribas, T. E. Angell, M. A. Su

The paper identifies clonally expanded CD8+ T cells driven by IL21 in ICI-thyroiditis using scRNA-seq and validates their role in thyroid inflammation.

bioRxiv · Dec 18, 2022 · PreprintImmunology

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy

M. G. Lechner, A. Y. Patel, W. Hugo, T. E. Angell, M. I. Cheng, M. S. Pioso, A. T. Hoang, N. Yakobian, E. C. McCarthy, H.-C. Chen, E. D. Rodriguez, L. Guo, M. Astourian, A. Drakaki, P. Famini, , M. A. Su

This study shows that inhibiting the IL-17A axis reduces immune-related adverse events in checkpoint inhibitor-treated mice without affecting anti-tumor efficacy.

bioRxiv · Jan 19, 2022Immunology